[SCHEDULE 13G/A] Inhibikase Therapeutics, Inc. Amended Passive Investment Disclosure
Perceptive reports 6.9% IKT stake via warrants
Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of 10,320,875 shares of Inhibikase Therapeutics, Inc. common stock through warrants, representing 6.9% of the class.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of 10,320,875 shares of Inhibikase Therapeutics, Inc. common stock through warrants, representing 6.9% of the class. This percentage is based on 139,535,900 shares outstanding as of August 4, 2026 and assumes exercise of the warrants held by the reporting group.
The Master Fund directly holds (i) pre-funded warrants for 790,000 shares at an exercise price of $0.001 per share, (ii) common warrants for 3,357,211 shares at $1.37 per share, and (iii) common warrants for 6,173,664 shares at $1.49 per share. The warrants contain a 9.99% beneficial ownership limitation, which currently permits exercise for up to 10,320,875 shares. Perceptive Advisors serves as investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors.
Key Figures
Beneficially owned shares:10,320,875 sharesOwnership percentage:6.9%Shares outstanding:139,535,900 shares+4 more
7 metrics
Beneficially owned shares10,320,875 sharesShares of Inhibikase common stock beneficially owned through warrants by the reporting persons
Ownership percentage6.9%Percentage of Inhibikase common stock class beneficially owned by each reporting person
Shares outstanding139,535,900 sharesInhibikase common stock outstanding as of August 4, 2026, used for ownership calculations
Pre-funded warrant exercise price$0.001 per shareExercise price on 790,000 pre-funded warrants held by the Master Fund
Common warrant exercise price$1.37 per shareExercise price on 3,357,211 common warrants held by the Master Fund
Common warrant exercise price$1.49 per shareExercise price on 6,173,664 common warrants held by the Master Fund
Beneficial ownership cap9.99%Maximum beneficial ownership allowed under the terms of the warrants
Key Terms
beneficially own, Pre-Funded Warrants, common warrants, Section 13(d) of the Securities Exchange Act of 1934, +1 more
5 terms
beneficially ownregulatory
"the Reporting Persons would beneficially own, as determined in accordance with Section 13(d)"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
Pre-Funded Warrantsfinancial
"pre-funded warrants (the "Pre-Funded Warrants") to purchase 790,000 shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
common warrantsfinancial
"common warrants to purchase 3,357,211 shares of Common Stock"
A common warrant is a tradable instrument that gives its holder the right to buy a company’s common shares at a fixed price within a set time period, similar to a coupon that can be redeemed later to purchase stock. Investors care because exercising warrants can boost potential gains if the stock rises, but it can also dilute existing shareholders by increasing the number of shares outstanding, which can lower per-share value.
Section 13(d) of the Securities Exchange Act of 1934regulatory
"as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934"
Section 13(d) of the Securities Exchange Act of 1934 is a U.S. rule that requires anyone who buys more than 5% of a public company’s shares to publicly disclose who they are, how many shares they own, and their intentions toward the company. For investors, this is like a neighborhood alert when someone acquires a large stake in a building: it reveals potential changes in control or strategy that could affect the stock’s price, governance, or future direction.
investment managerfinancial
"Perceptive Advisors serves as the investment manager of the Master Fund"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many Inhibikase Therapeutics (IKT) shares do the Perceptive entities beneficially own?
The Perceptive entities report beneficial ownership of 10,320,875 shares of Inhibikase common stock, all through warrants held by Perceptive Life Sciences Master Fund, Ltd., with no shares held directly by Perceptive Advisors or Joseph Edelman.
What percentage of Inhibikase Therapeutics (IKT) does Perceptive report owning?
Perceptive Advisors, Joseph Edelman and the Master Fund each report owning 6.9% of Inhibikase’s common stock. This is calculated using 139,535,900 shares outstanding as of August 4, 2026, plus the shares underlying their exercisable warrants.
What warrant positions in IKT does Perceptive Life Sciences Master Fund hold?
The Master Fund holds 790,000 pre-funded warrants at $0.001 per share, 3,357,211 common warrants at $1.37 per share, and 6,173,664 common warrants at $1.49 per share, all for Inhibikase common stock, subject to a beneficial ownership cap.
What is the 9.99% beneficial ownership limitation in the IKT warrants?
The warrants provide they cannot be exercised if doing so would cause the reporting persons to beneficially own over 9.99% of Inhibikase’s outstanding common stock. As of this filing, that cap allows exercise for up to 10,320,875 shares.
Who are the reporting persons on this Inhibikase Therapeutics (IKT) Schedule 13G/A?
The reporting persons are Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. Perceptive Advisors acts as investment manager to the Master Fund, and Edelman is the managing member of Perceptive Advisors.
Does Joseph Edelman directly hold any IKT shares or warrants?
The filing states that neither Perceptive Advisors nor Joseph Edelman directly holds any shares of Inhibikase common stock or warrants. All reported positions are held directly by Perceptive Life Sciences Master Fund, Ltd.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 3)
INHIBIKASE THERAPEUTICS, INC.
(Name of Issuer)
Common Stock, $0.001 par value
(Title of Class of Securities)
45719W205
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
45719W205
1
Names of Reporting Persons
Perceptive Advisors LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
10,320,875.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
10,320,875.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
10,320,875.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.9 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
CUSIP Number(s):
45719W205
1
Names of Reporting Persons
Joseph Edelman
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
10,320,875.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
10,320,875.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
10,320,875.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.9 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP Number(s):
45719W205
1
Names of Reporting Persons
Perceptive Life Sciences Master Fund, Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
10,320,875.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
10,320,875.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
10,320,875.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.9 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
INHIBIKASE THERAPEUTICS, INC.
(b)
Address of issuer's principal executive offices:
1000 N. West Street, Suite 1200, Wilmington, DE, 19801
Item 2.
(a)
Name of person filing:
The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value $0.001 per share (the "Common Stock") of INHIBIKASE THERAPEUTICS, INC. (the "Issuer") are:
(i) Perceptive Advisors LLC ("Perceptive Advisors")
(ii) Joseph Edelman ("Mr. Edelman")
(iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Reporting Persons is:
51 Astor Place, 10th Floor, New York, NY 10003
(c)
Citizenship:
Perceptive Advisors is a Delaware limited liability company.
Mr. Edelman is a United States citizen.
The Master Fund is a Cayman Islands corporation.
(d)
Title of class of securities:
Common Stock, $0.001 par value
(e)
CUSIP No.:
45719W205
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 139,535,900 shares of Common Stock outstanding as of August 4, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 11, 2026, and assume the exercise of Warrants (as defined below) held by the Reporting Persons for 10,320,875 shares of Common Stock.
Neither Perceptive Advisors nor Mr. Edelman directly holds any shares of Common Stock or Warrants. The Master Fund directly holds (i) pre-funded warrants (the "Pre-Funded Warrants") to purchase 790,000 shares of Common Stock at an exercise price of $0.001 per share, (ii) common warrants to purchase 3,357,211 shares of Common Stock at an exercise price of $1.37 per share, and (iii) common warrants to purchase 6,173,664 shares of Common Stock at an exercise price of $1.49 per share (together with the Pre-Funded Warrants, the "Warrants"). The terms of the Warrants provide that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 9.99% of the shares of Common Stock then issued and outstanding. As of the date hereof, this limitation permits the Reporting Persons to exercise Warrants for up to 10,320,875 shares of Common Stock. Perceptive Advisors serves as the investment manager of the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors.
(b)
Percent of class:
Perceptive Advisors: 6.9%
Mr. Edelman: 6.9%
Master Fund: 6.9%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Perceptive Advisors: 0
Mr. Edelman: 0
Master Fund: 0
(ii) Shared power to vote or to direct the vote:
Perceptive Advisors: 10,320,875
Mr. Edelman: 10,320,875
Master Fund: 10,320,875
(iii) Sole power to dispose or to direct the disposition of:
Perceptive Advisors: 0
Mr. Edelman: 0
Master Fund: 0
(iv) Shared power to dispose or to direct the disposition of:
Perceptive Advisors: 10,320,875
Mr. Edelman: 10,320,875
Master Fund: 10,320,875
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
